Every 10-Q that Soligenix, Inc. (SNGX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SNGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNGX filings page.
Soligenix, Inc. is a development-stage biopharmaceutical company with two segments and no revenue in the three or six months ended June 30, 2026. Operating expenses declined year over year, with research and development at $2.76 million and general and administrative at $2.23 million for the first half of 2026, leading to a six‑month net loss of $4.81 million versus $5.65 million in 2025.
Cash and cash equivalents were $9.81 million and working capital $6.50 million at June 30, 2026. Management expects existing cash to support operations into the second quarter of 2028, yet explicitly concludes that substantial doubt exists about the company’s ability to continue as a going concern, given ongoing losses and uncommitted funding beyond its at‑the‑market equity program.
During the first half, Soligenix raised $6.04 million via its Rodman at‑the‑market facility, increasing common shares outstanding to 21.64 million. After an interim futility analysis in April 2026, the Board terminated development of its lead HyBryte™ CTCL program in June 2026. The company also disclosed a Nasdaq notice for failure to meet the $1.00 minimum bid price, with an initial compliance period through December 7 2026.
Soligenix, Inc. reported a net loss of $2.8 million for the three months ended March 31, 2026, similar to the prior-year period, with no revenue and operating expenses of $2.9 million driven by research and development and general and administrative costs.
Cash and cash equivalents were $6.0 million and working capital was $2.9 million as of March 31, 2026. Management believes this cash can support operations into 2027, but explicitly states there is substantial doubt about the company’s ability to continue as a going concern because it does not have sufficient cash to fund operations for at least 12 months from the filing date.
The company’s lead CTCL program, HyBryte, suffered a major setback when the Data Monitoring Committee recommended the confirmatory Phase 3 FLASH2 trial halt for futility after an interim efficacy analysis in April 2026, and the company is analyzing the data. Soligenix continues to advance other rare disease candidates, including SGX302 for psoriasis and SGX945 for Behçet’s Disease, and maintains access to equity financing through a Rodman at-the-market facility with approximately $0.8 million of potential gross proceeds remaining as of May 1, 2026.
Soligenix filed its Q3 2025 10‑Q, reporting a smaller quarterly net loss and strengthened equity from recent financings. The company posted a net loss of $2,530,947 for the quarter and $8,184,191 year‑to‑date, with no 2025 revenue as it advances late‑stage programs. Research and development expense was $1,583,879 in the quarter and $5,202,573 year‑to‑date; general and administrative was $996,604 and $3,168,297, respectively.
Liquidity improved: cash and cash equivalents were $10,525,335, and stockholders’ equity rose to $7,597,976. The company completed a public offering on September 29, 2025 with total gross proceeds of approximately $7.5 million and executed ATM sales totaling $4,666,421 year‑to‑date. Convertible debt was fully repaid in February 2025.
Management states resources are sufficient for at least the next twelve months. Nasdaq notified the company in August about equity compliance; Soligenix believes it has regained compliance, supported by the September offering. The FLASH2 Phase 3 CTCL study is enrolling, with top‑line results anticipated in the second half of 2026.